Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
AssigneeMemorial Sloan Kettering Cancer Center
InventorsMichel Sadelain, Matthias Stephan
Life of this patent
Estimating the term…
Abstract
The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
Claims20
An immunoresponsive cell comprising an exogenous co-stimulatory ligand and a receptor that binds an antigen, wherein the exogenous co-stimulatory ligand is CD80.
An immunoresponsive cell comprising a receptor that binds to an antigen, and a nucleic acid molecule encoding an exogenous CD80.
An immunoresponsive cell comprising:
- a) a receptor that binds to an antigen, and b) a nucleic acid encoding a recombinant co-stimulatory ligand which is a heterologously expressed cytokine that is selected from the group consisting of an IL-2, an IL-12 and an IL-21.
An immunoresponsive cell comprising an exogenous co-stimulatory ligand and a receptor that binds an antigen, wherein the exogenous co-stimulatory ligand is 4-1BBL, a combination of 4-1BBL and CD80, or a combination of 4-1BBL and CD86.
Dependencies are inferred from the claim text.